JP2019513814A5 - - Google Patents

Download PDF

Info

Publication number
JP2019513814A5
JP2019513814A5 JP2018555644A JP2018555644A JP2019513814A5 JP 2019513814 A5 JP2019513814 A5 JP 2019513814A5 JP 2018555644 A JP2018555644 A JP 2018555644A JP 2018555644 A JP2018555644 A JP 2018555644A JP 2019513814 A5 JP2019513814 A5 JP 2019513814A5
Authority
JP
Japan
Prior art keywords
leucine
acetyl
acceptable salt
pharmaceutically acceptable
administering
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018555644A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019513814A (ja
JP7387264B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/GB2017/051090 external-priority patent/WO2017182802A1/en
Publication of JP2019513814A publication Critical patent/JP2019513814A/ja
Priority to JP2021185130A priority Critical patent/JP7506046B2/ja
Publication of JP2019513814A5 publication Critical patent/JP2019513814A5/ja
Application granted granted Critical
Publication of JP7387264B2 publication Critical patent/JP7387264B2/ja
Priority to JP2024096260A priority patent/JP2024123087A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018555644A 2016-04-19 2017-04-19 改善される運動性及び認知機能のためのアセチル-ロイシン又はその薬学的に許容される塩 Active JP7387264B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2021185130A JP7506046B2 (ja) 2016-04-19 2021-11-12 改善される運動性及び認知機能のためのアセチル-ロイシン又はその薬学的に許容される塩
JP2024096260A JP2024123087A (ja) 2016-04-19 2024-06-13 改善される運動性及び認知機能のためのアセチル-ロイシン又はその薬学的に許容される塩

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB201606834 2016-04-19
GB1606834.8 2016-04-19
PCT/GB2017/051090 WO2017182802A1 (en) 2016-04-19 2017-04-19 Acetyl-leucine or a pharmaceutically acceptable salt thereof for improved mobility and cognitive function

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021185130A Division JP7506046B2 (ja) 2016-04-19 2021-11-12 改善される運動性及び認知機能のためのアセチル-ロイシン又はその薬学的に許容される塩

Publications (3)

Publication Number Publication Date
JP2019513814A JP2019513814A (ja) 2019-05-30
JP2019513814A5 true JP2019513814A5 (enExample) 2022-01-21
JP7387264B2 JP7387264B2 (ja) 2023-11-28

Family

ID=58633040

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2018555644A Active JP7387264B2 (ja) 2016-04-19 2017-04-19 改善される運動性及び認知機能のためのアセチル-ロイシン又はその薬学的に許容される塩
JP2021185130A Active JP7506046B2 (ja) 2016-04-19 2021-11-12 改善される運動性及び認知機能のためのアセチル-ロイシン又はその薬学的に許容される塩
JP2024096260A Pending JP2024123087A (ja) 2016-04-19 2024-06-13 改善される運動性及び認知機能のためのアセチル-ロイシン又はその薬学的に許容される塩

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2021185130A Active JP7506046B2 (ja) 2016-04-19 2021-11-12 改善される運動性及び認知機能のためのアセチル-ロイシン又はその薬学的に許容される塩
JP2024096260A Pending JP2024123087A (ja) 2016-04-19 2024-06-13 改善される運動性及び認知機能のためのアセチル-ロイシン又はその薬学的に許容される塩

Country Status (26)

Country Link
US (4) US10905670B2 (enExample)
EP (2) EP3445351B1 (enExample)
JP (3) JP7387264B2 (enExample)
KR (4) KR102632670B1 (enExample)
CN (2) CN109069463B (enExample)
AU (2) AU2017252507B2 (enExample)
BR (1) BR112018071547A2 (enExample)
CA (2) CA3309723A1 (enExample)
DK (1) DK3445351T3 (enExample)
ES (1) ES2994242T3 (enExample)
FI (1) FI3445351T3 (enExample)
HR (1) HRP20241552T1 (enExample)
HU (1) HUE069219T2 (enExample)
IL (3) IL293266B2 (enExample)
LT (1) LT3445351T (enExample)
MD (1) MD3445351T2 (enExample)
MX (2) MX388461B (enExample)
PL (1) PL3445351T3 (enExample)
PT (1) PT3445351T (enExample)
RS (1) RS66142B1 (enExample)
RU (1) RU2745912C2 (enExample)
SG (2) SG10202106190RA (enExample)
SI (1) SI3445351T1 (enExample)
SM (1) SMT202400459T1 (enExample)
WO (1) WO2017182802A1 (enExample)
ZA (1) ZA201806849B (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3445351T (pt) 2016-04-19 2024-11-14 Intrabio Ltd Acetil-leucina ou um sal farmaceuticamente aceitável seu derivado para melhoria da mobilidade
TN2019000033A1 (fr) 2016-08-11 2020-07-15 Intrabio Ltd Agents thérapeutiques pour maladies neurodégénératives
GB201709459D0 (en) 2017-06-14 2017-07-26 Intrabio Ltd Treatment for migraine
CN120157593A (zh) 2018-12-06 2025-06-17 内在生物技术有限公司 乙酰基-亮氨酸的氘代类似物
CN119097618A (zh) * 2019-03-02 2024-12-10 内在生物技术有限公司 用于治疗疾病的亮氨酸、乙酰基亮氨酸和相关类似物
MD3989962T2 (ro) * 2019-06-28 2025-12-31 Intrabio Ltd Gb Terapie combinată cu acetil-leucină și miglustat pentru tratamentul unei boli de depozitare lizozomală
WO2021144720A1 (en) 2020-01-13 2021-07-22 Intrabio Ltd Treatment of late-onset neurodegenerative diseases in heterozygous npc1 gene mutation carriers
WO2025019570A1 (en) 2023-07-18 2025-01-23 Sytheon Ltd. Novel amino acid based salts, compositions and methods for treating skin and rejuvenating skin and extending longevity
WO2025166100A1 (en) 2024-02-02 2025-08-07 SynGAP Research Fund Compositions and methods for treating neurodevelopmental disorders

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060063827A1 (en) * 2004-09-23 2006-03-23 Yu Ruey J Systemic administration of therapeutic amino acids and N-acetylamino acids
US20070190070A1 (en) * 2004-09-03 2007-08-16 Zeldis Jerome B Methods of using and compositions comprising selective cytokine inhibitory drugs for the treatment and management of disorders of the central nervous system
FR2883180B1 (fr) * 2005-03-18 2007-05-25 Pierre Fabre Medicament Sa Utilisation de l'acetyl-leucine pour la preparation d'un medicament destine au traitement de troubles de l'equilibre
FR2905600B1 (fr) * 2006-09-13 2010-01-15 Pf Medicament Traitement des vertiges par l'acetyl-l-leucine.
US20080097606A1 (en) * 2006-10-19 2008-04-24 Cragg Andrew H Knee joint prosthesis and hyaluronate compositions for treatment of osteoarthritis
AU2007352854A1 (en) * 2007-05-08 2008-11-13 Northern Innovations And Formulations Corp. Branched-chain amino acid composition for improving skeletal muscle protein metabolism
WO2011025518A1 (en) * 2009-08-27 2011-03-03 Albert Einstein College Of Medicine Of Yeshiva University Cognitive function training to improve motor ability
TN2010000251A1 (fr) * 2010-06-03 2011-11-11 Rekik Raouf N-acetyl-dl-leucine medicament neuro et retino protecteur
WO2012060844A1 (en) * 2010-11-05 2012-05-10 Biotie Therapies, Inc A2a antagonists as cognition and motor function enhancers
TN2010000566A1 (en) * 2010-12-03 2012-05-24 Rekik Raouf Folic acid - ramipril combination : cell protective neuroprotective and retinoprotective ophtalmologic drugs
PT3445351T (pt) * 2016-04-19 2024-11-14 Intrabio Ltd Acetil-leucina ou um sal farmaceuticamente aceitável seu derivado para melhoria da mobilidade
EP3697406A1 (en) * 2017-10-18 2020-08-26 IntraBio Ltd Therapeutic agents for improved mobility and cognitive function and for treating neurodegenerative diseases and lysosomal storage disorders

Similar Documents

Publication Publication Date Title
JP2006506378A5 (enExample)
JP6466540B2 (ja) 多発性硬化症を治療するためのPPARγアゴニスト
JP7506046B2 (ja) 改善される運動性及び認知機能のためのアセチル-ロイシン又はその薬学的に許容される塩
US11083735B2 (en) Methods for treating sleep disorders, sleep disturbances, and related symptoms using aminosterol compositions
US20070270347A1 (en) Methods of Treating Constipation by Administration of Nerve Growth Factor
AU2017277005B2 (en) Lipids with odd number of carbon atoms and their use as pharmaceutical composition or nutritional supplement
JP2009537553A5 (enExample)
JP2009508854A (ja) 睡眠時呼吸障害の予防及び治療方法及び手段
JP2012197304A (ja) ミオパシー関連性の覚醒障害を矯正することが意図される医薬品を製造するためのモダフィニルの使用
JP2022533968A5 (enExample)
CN107835695A (zh) 用于治疗自闭症的组合物和方法
US20200299411A9 (en) Composition and method for treating alzheimer's disease
KR102693607B1 (ko) 하지 불안 증후군을 치료하기 위한 치료제
US20180221315A1 (en) Combination therapy using acamprosate and d-cycloserine
WO2007046347A1 (ja) 筋萎縮性側索硬化症患者の運動神経保護用医薬
IL272834B2 (en) Amantadine compositions, preparations thereof, and methods of use
JP2021530568A5 (enExample)
JP2022526643A5 (enExample)
RU2391095C1 (ru) Фармацевтическая композиция, включающая холина альфосцерат и гопантеновую кислоту (или ее соль), для лечения недостаточности кровообращения мозга и эректильной дисфункции
EP4420660A1 (en) Use of edaravone in treatment of autism spectrum disorder
RU2369393C2 (ru) Применение окскарбазепина для лечения диабетической нейропатической боли и для улучшения сна
JP2008535907A5 (enExample)
CA2330568A1 (en) Use of 4-piperidinemethanol derivatives in treatment of neurodevelopmental disorders
JP2022071083A (ja) うつ病を予防または治療するための安息香酸またはその塩および誘導体
US20200038417A1 (en) Methods and compositions for treating cognitive impairment